Long-Acting Injectable Antipsychotics: Evidence of Effectiveness and Use
Authors:
Open Access
- 1 May 2013
- journal article
- research article
- Published by SAGE Publications in The Canadian Journal of Psychiatry
- Vol. 58 (5_suppl) , 5-13
Abstract
Objective: To review the evidence for the role of long-acting injectable (LAI) antipsychotics (APs), especially the second-generation AP (SGA) LAIs, in the treatment of schizophrenia and to discuss the use rates of LAIs in Canada. Method: A search of online medical databases was conducted of the published literature (1995–2012) of the effects of LAIs on the domains of remission, adherence, relapse, and hospitalization. Results obtained from randomized controlled trials (RCTs), systematic reviews, meta-analyses, and large-scale observational studies were included. Expert consensus data were also solicited on LAI use within a Canadian context. Results: While the efficacy of LAIs, compared with placebo, is well established, the evidence from RCTs is equivocal for any specific advantage for SGA LAIs, compared with oral medications, probably owing to challenges in conducting such RCTs. Evidence from methodologically less rigorous studies and from clinical practice suggests some advantages in achieving and maintaining remission, risk of relapse, and hospitalization. The rate of LAI (first-generation AP and SGA) use from published outpatient studies is low at 6.3% in Canada, compared with 15% to 80% worldwide. However, there is a relatively high rate of use in specific early psychosis programs and in conjunction with community treatment orders in Canada. Conclusions: LAIs are at least as effective as oral APs in the treatment of psychotic disorders. The former may have specific advantages for patients who demonstrate covert nonadherence. The underuse of LAIs in Canada needs to be better understood and addressed.Keywords
This publication has 66 references indexed in Scilit:
- Long-acting injectable risperidone in partially adherent and nonadherent patients with schizophreniaNeuropsychiatric Disease and Treatment, 2011
- Effectiveness of injectable risperidone long-acting therapy for schizophrenia: data from the US, Spain, Australia, and BelgiumAnnals of General Psychiatry, 2011
- Once-monthly paliperidone injection for the treatment of schizophreniaNeuropsychiatric Disease and Treatment, 2010
- Relapse Prevention in Schizophrenia and Schizoaffective Disorder with Risperidone Long-Acting Injectable vs Quetiapine: Results of a Long-Term, Open-Label, Randomized Clinical TrialNeuropsychopharmacology, 2010
- A Controlled, Evidence-Based Trial of Paliperidone Palmitate, A Long-Acting Injectable Antipsychotic, in SchizophreniaNeuropsychopharmacology, 2010
- Testing Definitions of Symptom Remission in First-Episode Psychosis for Prediction of Functional Outcome at 2 YearsSchizophrenia Bulletin, 2009
- Oral versus injectable antipsychotic treatment in early psychosis: Post hoc comparison of two studiesClinical Therapeutics, 2008
- Use of Depot Antipsychotic Medications for Medication Nonadherence in SchizophreniaSchizophrenia Bulletin, 2008
- Effectiveness of antipsychotic treatments in a nationwide cohort of patients in community care after first hospitalisation due to schizophrenia and schizoaffective disorder: observational follow-up studyBMJ, 2006
- Depot Antipsychotic DrugsDrugs, 1994